A naukri.com initiative
Bioengineer
4d
233
Image Credit: Bioengineer
Supercharged Mitochondria Drive Aging-Linked Blood Disorders
- Researchers at The Jackson Laboratory have discovered how age-related mutations enhance the proliferative capabilities of blood stem cells, shedding light on potential therapeutic strategies for hematologic disorders.
- Genetic mutations, particularly in the gene Dnmt3a, lead to significant changes in cellular metabolism in blood stem cells, offering insights into the mechanisms driving clonal hematopoiesis and age-related diseases.
- Mutant hematopoietic stem cells show increased mitochondrial membrane potential and ATP production, promoting their clonal expansion within the bone marrow and contributing to clonal hematopoiesis.
- Mitochondrial-targeting agents like MitoQ and metformin have demonstrated the ability to selectively impair mutant stem cells while sparing normal cells, revealing new therapeutic opportunities.
- The study highlights the unexpected link between Dnmt3a mutations, mitochondrial metabolism, and the competitive advantage of mutant stem cells, offering a novel perspective on disease interception.
- The findings have implications for precision medicine in geriatric hematology by targeting the metabolic vulnerabilities of mutant blood stem cells to prevent the development of severe blood cancers and age-related diseases.
- Future research will explore the broader applicability of mitochondrial-targeting therapies across different genetic variants driving clonal hematopoiesis and the long-term effects of manipulating mitochondrial function in stem cells.
- Human hematopoietic stem cells carrying DNMT3A mutations respond similarly to mitochondrial inhibitors, validating the cross-species potential of mitochondrial-targeting agents in managing clonal hematopoiesis.
- The interdisciplinary approach combining molecular biology, genetics, metabolism, and pharmacology exemplified in this study represents a transformative shift in combating aging-related blood disorders through innovative therapeutic strategies.
- Clinical trials testing mitochondrial inhibitors and metabolic modulators in older populations with clonal hematopoiesis could revolutionize preventive care, offering a proactive approach to reducing morbidity and mortality associated with aging-related diseases.
Read Full Article
14 Likes
For uninterrupted reading, download the app